36304-81-1

Upstream product

• 50-00-0 formaldehyd 
• 1078151-90-2 C₂₅H₂₉NO₂ 
• 36309-11-2 (+)-1-p-methylbenzyl-2-methyl-1,2,3,4,5,6,7,8-octahydroisoquinoline 
• 38973-16-9 2-methyl-1-(4-methyl-benzyl)-1,2,3,4,5,6,7,8-octahydro-isoquinoline 
• 75-16-1 methylmagnesium bromide 
• 125-71-3 dextromethorphan 
• 1216910-39-2 (+)-17-ethylcarbamate-3-methyl-(9α,13α,14α)-morphinan 
• 1216910-34-7 (4bS,8aS,9S)-ethyl 3-(((trifluoromethyl)sulfonyl)oxy)-6,7,8,8a,9,10-hexahydro-5H-9,4b-(epiminoethano)-phenanthrene-11-carboxylate 
• 524713-55-1 (4bS,8aS,9S)-ethyl 3-methoxy-6,7,8,8a,9,10-hexahydro-5H-9,4b-(epiminoethano)phenanthrene-11-carboxylate 
• 1079043-47-2 (4bS,8aS,9S)-ethyl 3-hydroxy-6,7,8,8a,9,10-hexahydro-5H-9,4b-(epiminoethano)phenanthrene-11-carboxylate 

Downstream Products

• 36304-84-4 Dimemorfan phosphate 

Relevant academic research and scientific papers

Method for preparing high-purity dimemorfan

The invention relates to the technical field of drug synthesis, and particularly relates to a method for preparing a key intermediate dimemorfan of a nonaddictive central antitussive dimemorfan phosphate. The method is characterized by comprising the following steps in sequence: using (S)-1-(4-methylbenzyl)-1,2,3,4,5,6,7,8-octahydroisoquinoline-L-mandelate as a starting raw material, and adding analkali to neutralize for removing mandelic acid; afterwards, adding a formylation reagent to obtain an intermediate (S)-1-(4-methylbenzyl)-N-formyl-1,2,3,4,5,6,7,8-octahydroisoquinoline; afterwards,adding a cyclization reagent to carry out a cyclization reaction, so a to obtain an intermediate 3-methyl-17-formyldextromethorphan; afterwards, carrying out a reduction reaction or hydrolyzing, and then carrying out a methylation reaction, so that dimemorfan is obtained. The method provided by the invention is not only short in preparation cycle, but also, more importantly, is used for greatly improving a product yield, and the impurity content is obviously reduced.

Preparation method of dimemorfan phosphate

The invention relates to the field of pharmaceutical chemistry, in particular to a preparation method of a non-addictive central antitussive dimemorfan phosphate. The method is characterized by: taking the basic group dextromethorphan of the drug dextromethorphan hydrobromide marketed for years as the starting raw material, conducting methoxymethylation, and then salifying the product with phosphoric acid to obtain dimemorfan phosphate. The method provided by the invention has the advantages of concise process route, high product purity and low cost, and is suitable for industrial production.

Concise synthesis of dimemorfan (DF) starting from 3-hydroxymorphinan (3-HM)

Dimemorfan (DF) has been known to possess neuroprotective properties. While this promising compound deserves further biological evaluation, synthetic methods have not improved since Murakami group unveiled the synthetic efforts in 1972. Herein a succinct synthesis toward DF from commercially available 3-hydroxymorphinan (3-HM) is disclosed. Other morphinan analogs have been effectively prepared by adopting the similar methodology.

Opioid and opioid-like compounds and uses thereof

The present invention relates to opioid and opioid-like compounds, and pharmaceutical formulations thereof, and use thereof for prevention and treatment of disorders such as septic shock and organ damage.

OPIOID AND OPIOID-LIKE COMPOUNDS AND USES THEREOF

The present invention relates to opioid and opioid-like compounds, and pharmaceutical formulations containing the same and methods of use thereof. Uses of the present invention include, but are not limited to, use for the prevention and treatment of septic shock and other disorders. The compounds described herein can be water soluble and can act through mechanisms mediated through pathways other than opiate receptors.